 |
Email the Society |
 |
Donations |
ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
Mailing address:
GPO Box 383,
Adelaide,
South Australia 5001
Office:
266 Port Road,
Hindmarsh,
South Australia 5007
Ph: (08) 8346 3237
('834 MECFS')
Office Hours:
Wednesdays, 10am-3pm
Support Line:
(Mondays and Thursdays,
10am-3pm)
Ph: (08) 8346 3237
SA country callers:
Ph: 1300 128 339
(local call)
FIBROMYALGIA HELP: Contact Fibromyalgia SA at the Arthritis Foundation of SA 118 Richmond Road, Marleston 5033 Ph: (08) 8379 5711 |
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc is a member of Charity Direct.
|
Disclaimer
ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
FDA gets application for new Fibromyalgia drug
Thursday 17 December 2009
About.com's Adrienne Dellwo reports on a potential new drug for Fibromyalgia:
Jazz Pharmaceuticals, Inc. says it has submitted a New Drug Application to the FDA for JZP-6 (sodium oxybate) as a fibromyalgia treatment.
Sodium oxybate is the active ingredient in the drug Xyrem, which currently is on the market for narcolepsy. Many people take it off label for fibromyalgia.
Jazz says the application includes results from two Phase III clinical trials showing the drug significantly decreased pain and fatigue, and improved both daily function and sleep quality.
• Learn more about JZP-6 (Sodium Oxybate)
The above originally appeared here.
|
More Fibromyalgia News |
blog comments powered by Disqus
Previous Page |
